Main > ONCOLOGY (**) > Breast Cancer>HER2+>MET *** > Treatment > KR. C. BioSimilar TrastuzuMAb *

---

KR. C. BioSimilar TrastuzuMAb *'s subsections
(*) EU Approval Date: 2018. 02.14
(*) KR Launch Year: 2017
Company
TradeMark

KR. C. BioSimilar TrastuzuMAb *'s products
This section has no products